Editas Medicine, Inc. (NasdaqGS:EDIT) has a current EV or Enterprise Value of 705999. The EV displays how the market assigns value to a firm as a whole. EV is generally a modification of market cap, as it incorporates debt and cash for assessing a firm’s valuation. Tracking EV may help when comparing companies with different capital structures. EV can help investors gain a truer sense of whether a company is undervalued or not.
When it comes to the stock market, many traders rely on technical analysis to identify trades. With technical analysis, it is generally believed that stock price movements follow trends. When the trend is determined, the thought is that price movements in the future are more likely to go in the same direction as the trend, and not against it. Another aspect of technical analysis is the idea that history tends to repeat itself especially regarding the movement of the stock’s price. Technical analysts will use chart patterns to help study market moves and identify these trends. Some traders will use highly complex charts while others may only follow a few major indicators.
Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Editas Medicine, Inc. (NasdaqGS:EDIT) is 71.125300. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Editas Medicine, Inc. (NasdaqGS:EDIT) is 94.248500. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 76.819600.
Investors can employ various techniques in order to study stocks. Two of the most widely used techniques are fundamental and technical analysis. Fundamental analysis includes crunching the numbers for specific companies. This may involve reviewing the cash flow statement, income statement, and balance sheet. In essence, fundamental analysts are trying to figure out the company’s value. Once the value of a company is determined, the investor can then make investment decisions based on the research. Using this method, a stock that is trading underneath the intrinsic value may be considered a good pick. Technical traders typically hold the view that all the data they need to know about a stock can be discovered to using charts.
Currently, Editas Medicine, Inc. (NasdaqGS:EDIT)’s ROIC is -1.741298. The ROIC 5 year average is -1.551157 and the ROIC Quality ratio is -0.576559. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a company is at turning capital into profits. ROIC may be a good measure to view when examining whether or not a company is able to invest wisely. ROIC may also be an important metric for the value investor who is trying to determine the company’s moat. Editas Medicine, Inc. (NasdaqGS:EDIT) has a current Value Composite Score of 93. Using a scale from 0 to 100, a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company. This ranking was developed by James O’Shaughnessy using six different valuation ratios including price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings, and shareholder yield.
Investors seeking value in the stock market may be eyeing the Magic Formula Rank or MF Rank for Editas Medicine, Inc. (NasdaqGS:EDIT). Presently, the company has a MF Rank of 17020. The Magic Formula was devised and made popular by Joel Greenblatt in his book “The Little Book That Beats the Market”. Greenblatt’s formula helps find stocks that are priced attractively with a high earnings yield, or strong reported profits in comparison to the market value of the company. To spot opportunities in the market, investors may be searching for stocks that have the lowest combined MF Rank.
Market watchers may also be following some quality ratios for Editas Medicine, Inc. (NasdaqGS:EDIT). Currently, the company has a Gross Margin (Marx) ratio of -0.176454. This calculation is based on the research by University of Rochester professor Robert Novy-Marx. Marx believed that a high gross income ratio was a sign of a quality company. Looking further, Editas Medicine, Inc. (NasdaqGS:EDIT) has a Gross Margin score of 50.00000. This score is based on the Gross Margin (Marx) metric using a scale from 1 to 100 where a 1 would be seen as positive, and a 100 would be viewed as negative.
When compared to technical analysis, fundamental analysis typically uses a longer-term approach. Chartists may use a time horizon of days, hours, or even minutes. Fundamental analysis may track data going back many years. The difference in timeframe between the two can be seen with how each investing style may be used. Traders may only be looking to make quick trades and capitalize on short-term market movements. Longer-term investors may be looking to hold an investment for months or even years. Some investors will use a combination that studies the technicals and the fundamentals. Fundamentals may be used to identify which stock to buy, while viewing the technicals can be used to sort out the timing of the trade.
The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Editas Medicine, Inc. (NasdaqGS:EDIT) for last month was 0.81192. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Editas Medicine, Inc. (NasdaqGS:EDIT) is 0.61299.
Price Range 52 Weeks
Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Editas Medicine, Inc. (NasdaqGS:EDIT) over the past 52 weeks is 0.460000. The 52-week range can be found in the stock’s quote summary.
The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements. The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth. The C-Score of Editas Medicine, Inc. (NasdaqGS:EDIT) is 1.00000. The score ranges on a scale of -1 to 6. If the score is -1, then there is not enough information to determine the C-Score. If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.
When looking at technical analysis, one of the leading concepts is that of the trend. Chartists are constantly looking to identify trends to help determine which way a stock price is moving. Trends may not always be easy to spot, but they can be highly useful when identified. When looking at the stock market, an example of an upward trend is generally classified as a stock price that over time keeps reaching higher highs and higher lows. On the flip side, a downward trend is usually identified by spotting a stock that has been hitting lower lows and lower highs. Defining trends may take the novice trader some time to figure out, but learning how to properly study charts may help bring in steady profits in the future.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.